CIBC Private Wealth Group
CRNX icon

CIBC Private Wealth Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

CIBC Private Wealth Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32
Closed -$818 – 3130
2025
Q1 		$818 Buy
+32
New +$1.2K ﹤0.01% 2842
2024
Q4 		– Sell
-15
Closed -$767 – 3028
2024
Q3 		$767 Sell
15
-919
-98% -$47.4K ﹤0.01% 2938
2024
Q2 		$42.4K Buy
+934
New +$43.1K ﹤0.01% 1741

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Private Wealth Group's CRNX Position: Q2 2025 in Review

CIBC Private Wealth Group sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 32 shares — an estimated $818 sold.

CIBC Private Wealth Group first reported a position in CRNX in Q2 2024 and held it in 3 quarters. The position peaked at $42.4K in Q2 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • CIBC Private Wealth Group reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 32 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $818.
  • CIBC Private Wealth Group first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • CIBC Private Wealth Group's Crinetics Pharmaceuticals position peaked at $42.4K in Q2 2024.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on CIBC Private Wealth Group's 13F filing for Q2 2025, filed 12 Aug 2025.